Pediatric Myocarditis in the Post-COVID-19 Era: Lessons from a Resource-Limited Setting

Abstract

Pediatric myocarditis remains one of the most challenging conditions encountered in clinical cardiology. Its presentation is often nonspecific, its diagnosis frequently elusive, and its clinical course highly variable, ranging from complete recovery to fulminant heart failure, arrhythmias, transplantation, or death. Consequently, clinicians continue to face difficult decisions regarding diagnostic evaluation, therapeutic intensity, and long-term surveillance of affected children [1]. In this context, the study by Jamil et al.[2] provides valuable local evidence regarding the burden, clinical characteristics, and short-term outcomes of pediatric myocarditis in Pakistan during the post-COVID-19 era. In a region where epidemiological and outcome data remain limited, this report offers important insights into a disease that continues to impose substantial clinical and healthcare challenges. Since the emergence of the COVID-19 pandemic, increasing attention has focused on myocardial involvement in children following SARS-CoV-2 infection. Reports have documented rises in myocarditis diagnoses associated with acute COVID-19 infection, post-infectious inflammatory syndromes, and multisystem inflammatory syndrome in children (MIS-C) [3]. Against this backdrop, the findings reported by Jamil et al. are particularly noteworthy. Among 892 pediatric cardiology admissions, 76 children were diagnosed with myocarditis, accounting for 8.5% of all admissions, while nearly half demonstrated evidence of prior SARS-CoV-2 exposure. Although hospital-based proportions should not be interpreted as population incidence rates, the observed burden underscores the considerable impact that myocarditis continues to exert on tertiary pediatric cardiac services in Pakistan. The severity of illness observed in this cohort deserves particular attention. The reported median left ventricular ejection fraction of only 24.5% reflects profound myocardial dysfunction at presentation. Furthermore, nearly all patients required inotropic support, and the observed mortality rate of 17.1% highlights the potentially devastating nature of the disease [4]. These findings reinforce a well-recognized clinical reality: pediatric myocarditis frequently presents late in its course, often after significant ventricular dysfunction and hemodynamic compromise have already developed. Such challenges may be further amplified in resource-limited environments where delays in referral, limited diagnostic capabilities, and restricted access to advanced heart failure therapies can adversely affect outcomes. An especially important observation from this study is the absence of significant differences in clinical presentation, laboratory findings, echocardiographic characteristics, or short-term outcomes between children with and without evidence of prior COVID-19 exposure. While SARS-CoV-2 has been clearly associated with myocardial injury, myocarditis, and MIS-C, these findings suggest that once clinically significant myocarditis develops, disease severity and short-term outcomes may be determined more by the extent of myocardial inflammation and ventricular dysfunction than by the specific infectious trigger itself. Although this interpretation should be approached cautiously given the modest sample size and observational design, it raises important questions regarding the pathophysiological similarities shared by myocarditis of different etiologies. The study also draws attention to a persistent challenge faced by healthcare systems across many low- and middle-income countries: limited access to advanced diagnostic technologies. Contemporary international guidelines recognize cardiac magnetic resonance imaging (CMR) as the preferred non-invasive modality for confirming myocardial inflammation, while endomyocardial biopsy remains the diagnostic reference standard in carefully selected cases [5]. However, both investigations remain unavailable or inaccessible in many resource-constrained settings. Consequently, clinicians often rely on a pragmatic combination of clinical assessment, cardiac biomarkers, electrocardiography, and echocardiography, as was done in this study. Although such approaches are often necessary, they may increase diagnostic uncertainty and potentially lead to both underdiagnosis and overdiagnosis. These realities highlight the urgent need for practical, evidence-based diagnostic algorithms tailored specifically for resource-limited environments. Another noteworthy finding is the predominance of very young children, with a median age of only two years. This contrasts with several reports from high-income countries, where myocarditis and COVID-19-related myocardial involvement have often been described more frequently among older children and adolescents. Whether this age distribution reflects regional epidemiological differences, distinct infectious etiologies, referral patterns, healthcare-seeking behavior, or demographic characteristics remains uncertain. Future multicenter studies incorporating broader geographic representation will be necessary to better understand these differences. Several limitations of the study merit consideration. The single-center design, relatively small sample size, absence of advanced imaging confirmation, and reliance on clinically based diagnostic criteria limit generalizability. Most importantly, the lack of long-term follow-up leaves unanswered questions regarding ventricular recovery, persistent systolic dysfunction, arrhythmia burden, exercise capacity, quality of life, and progression to dilated cardiomyopathy. These outcomes are particularly relevant because the consequences of pediatric myocarditis may extend far beyond hospital discharge, with some children experiencing chronic cardiovascular sequelae despite apparent early recovery. Nevertheless, this study provides an important contribution to the limited literature on pediatric myocarditis from South Asia. Beyond documenting disease burden, it highlights the realities of managing severe myocardial inflammation in resource-constrained settings, where clinicians must frequently make critical decisions without access to advanced diagnostic or therapeutic resources. The findings serve as a timely reminder that myocarditis remains a significant cause of pediatric morbidity and mortality and underscore the importance of early recognition, prompt referral, and strengthened pediatric cardiac care services. As the post-COVID-19 era continues to evolve, collaborative multicenter registries, standardized diagnostic pathways, and longitudinal outcome studies will be essential to better define the epidemiology, risk factors, and long-term consequences of pediatric myocarditis in low- and middle-income countries. Generating such evidence will be crucial not only for improving clinical outcomes but also for informing health policy and resource allocation aimed at reducing the burden of this potentially life-threatening disease. References Law YM, Lal AK, Chen S, Čiháková D, Cooper LT Jr, Deshpande S, et al. Diagnosis and management of myocarditis in children: a scientific statement from the American Heart Association. Circulation. 2021;144(6): e123–e135. DOI:10.1161/CIR.0000000000001001 Jamil M, Arshad MS, Adnan M, Mehwish F. Frequency, Clinical Characteristics, and Short-Term Outcomes of Pediatric Myocarditis in the Post-COVID-19 Era: A Tertiary Care Experience from Pakistan. Pak Heart J. 2026;59(03):1-2. DOI: 10.47144/phj.v59i3.3612 Patel T, Kelleman M, West Z, Peter A, Dove M, Butto A, et al. Comparison of multisystem inflammatory syndrome in children-related myocarditis, classic viral myocarditis, and COVID-19 vaccine-related myocarditis in children. J Am Heart Assoc. 2022;11:e024393. DOI: 10.1161/JAHA.121.024393 Williams JL, Jacobs HM, Lee S. Pediatric Myocarditis. Cardiol Ther. 2023;12(2):243-260. DOI: 10.1007/s40119-023-00309-6 Dawood I, Alhussein ST, Wadi WY, Abdalgadir RA, Mohammed SS, Ahmed EH. Viral myocarditis in pediatrics: A review of current diagnostic methods and future directions. Ann Pediatr Card. 2025;18:42-8. DOI: 10.4103/apc.apc_236_24